Warfarin Drug-Drug Interaction Monitoring
Warfarin exposure is most affected by CYP2C9 inhibitors (↑ INR/bleeding risk) and CYP2C9 inducers (↓ INR/thrombosis risk). Drug–drug interaction effects are often clinically significant at initiation, discontinuation, or dose changes of interacting drugs. [1] [2]
Drug Interaction Pattern Recognition (INR Increase vs INR Decrease)
INR Increase and Bleeding Risk (CYP2C9 inhibition and/or altered hemostasis)
The following commonly require close INR monitoring and dose adjustment due to increased warfarin effect:
- Antibiotics that inhibit CYP2C9
- Metronidazole
-
Trimethoprim–sulfamethoxazole (TMP-SMX) UC San Diego anticoagulation clinic guideline [2]
-
Amiodarone (complex interaction; INR can rise over weeks) UC San Diego anticoagulation clinic guideline
- Azole antifungals (eg, fluconazole, voriconazole) [1] [2]
- Some anticancer agents and other CYP2C9 inhibitors (eg, capecitabine) [1]
INR Decrease and Thrombosis Risk (CYP2C9 induction)
The following commonly require INR monitoring for loss of anticoagulant effect:
- Rifampin (strong inducer) [1] [2]
- Carbamazepine and phenobarbital (inducers) [1] [2]
Medication Selection Algorithm (Common High-Impact Classes)
Highest-yield CYP2C9 inhibitors to check on every prescription
- Metronidazole
- TMP-SMX
- Amiodarone
- Azole antifungals (eg, fluconazole, voriconazole)
- Fluvoxamine and other CYP2C9 inhibitors listed in the warfarin label [1] [2]
Highest-yield CYP2C9 inducers to check on every prescription
- Rifampin
- Carbamazepine
- Phenobarbital
- St John’s wort is also implicated as an inducer-associated interaction in clinical references [1] [2]
Monotherapy vs Combination Therapy Considerations
When warfarin is combined with other therapies that increase bleeding risk, monitoring intensity should be increased beyond INR alone.
- Concomitant antiplatelet therapy increases bleeding risk in patients treated with vitamin K antagonists and is commonly flagged as a caution category in clinical guidance for VKAs. [3]
Initiation/Discontinuation Timing That Drives INR Change
INR changes commonly begin after interacting therapy starts and require proactive INR checks during the expected interaction window.
- For CYP2C9 inhibitor antibiotics (eg, metronidazole and TMP-SMX), INR monitoring is commonly recommended early in therapy because INR can rise within the first several days. [4]
- For amiodarone, the INR rise can be delayed and prolonged monitoring is needed. UC San Diego anticoagulation clinic guideline
Common Pitfalls to Avoid
- Missing INR re-check after starting or stopping a high-risk interacting medication is a frequent cause of supratherapeutic INR and bleeding. [2]
- Underestimating antibiotic interactions is common because multiple antibiotics inhibit CYP2C9 and can substantially increase warfarin effect. [3]
- Relying only on “drug name familiarity” can fail because INR effect depends on the specific inhibitor/inducer and timing; labeling and interaction references should be used for every medication change. [2]
Practical Monitoring Triggers During Therapy
Close monitoring is recommended when any of the following occurs:
- Start of a known CYP2C9 inhibitor (eg, metronidazole, TMP-SMX, azoles, amiodarone). UC San Diego anticoagulation clinic guideline [1]
- Start of a known CYP2C9 inducer (eg, rifampin, carbamazepine, phenobarbital). [1] [2]
- Stop of an interacting drug (INR often moves back toward baseline in the opposite direction). [2]
High-Yield Interaction “Checklist” for Real-World Prescribing
The following should be treated as “must-check” interaction categories for warfarin:
- Metronidazole
- TMP-SMX
- Amiodarone
- Azole antifungals (eg, fluconazole, voriconazole)
- Rifampin and other strong inducers (eg, carbamazepine, phenobarbital) UC San Diego anticoagulation clinic guideline [1]